Core Insights - Rigel Pharmaceuticals is set to present seven posters at the 2025 ASCO Annual Meeting and EHA Congress, focusing on their hematology and oncology product portfolio, particularly GAVRETO® and REZLIDHIA® [1][2][3] Group 1: GAVRETO® (pralsetinib) - GAVRETO is being highlighted for its treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC), with final data from the Phase 1/2 ARROW study demonstrating a 70.3% overall response rate (ORR) and a median duration of response (DOR) of 19.1 months [6][8] - The study also reported a median overall survival (OS) of 44.3 months and a median progression-free survival (PFS) of 13.1 months, with notable differences in PFS across regions: 25.9 months in the U.S. compared to 12.6 months in Asia and 12.9 months in Europe [6][8] - Additional data from the ARROW study indicated promising anti-tumor activity in various RET fusion-positive solid tumors, suggesting GAVRETO's potential to address unmet medical needs [3][6] Group 2: REZLIDHIA® (olutasidenib) - REZLIDHIA is being presented for its efficacy in relapsed or refractory acute myeloid leukemia (AML), with data supporting its use in earlier lines of treatment, particularly for patients with mutated isocitrate dehydrogenase-1 (mIDH1) [3][5] - In a pivotal cohort of R/R AML patients, REZLIDHIA showed a 50% ORR and a 30% complete response (CR) rate, with a median duration of CR of 17.6 months [12] - The drug demonstrated clinically meaningful activity and a durable response in patients with primary refractory AML, indicating its potential as an effective therapeutic option for this challenging patient population [12][19] Group 3: Clinical Data and Comparisons - A matching-adjusted indirect comparison (MAIC) analysis of olutasidenib versus ivosidenib in mIDH1 R/R AML showed comparable response rates, with olutasidenib favoring longer durations of CR [11] - Final results from the Phase 2 portion of the ARROW study in RET fusion-positive solid tumors other than NSCLC indicated an ORR of 46.4%, including a 100% ORR in pancreatic cancer [11] - The data validate RET fusions as a tissue-agnostic target, supporting the promising potential of pralsetinib to address unmet medical needs across various tumor types [11][12]

Group 1 - M-tron Industries, Inc. will hold its 2025 Annual Meeting of Stockholders on June 10, 2025, at the Harvard Club of New York City [1] - An Investor Presentation will take place on the same day at 8:30 a.m. Eastern Time, providing detailed information on the company's strategic direction, recent business developments, and financial performance [1] - Investors are required to RSVP by June 6, 2025, to attend the events, and a unique QR code will be provided for entry [2] Group 2 - M-tron Industries, Inc. was founded in 1965 and specializes in designing, manufacturing, and marketing high-reliability frequency and spectrum control products [3] - The company has design and manufacturing facilities in Orlando, Florida, and Yankton, South Dakota, along with a sales office in Hong Kong and a manufacturing facility in Noida, India [3]

Semiconductor company Analog Devices (ADI -4.72%) published its latest quarterly earnings report Thursday morning, but despite its estimates-beating performance, investors sold out of the stock.They left it with a more than 4% drop in share price on the day, on concerns that a lingering tariff war could badly affect its fundamentals. That decline compared unfavorably to the S&P 500's (^GSPC -0.04%) marginal slide.Powerful double-digit growthFor its fiscal second quarter of 2025, Analog Devices' revenue came ...

Benefiting from strong demand for their wireless and broadband services, AT&T (T)  and Verizon (VZ)  stock have provided a pleasant hedge against market volatility this year.Not too far off their 52-week highs, AT&T’s stock is up +20% year to date, with Verizon shares sitting on respectable gains of +9% compared to the S&P 500 and the Nasdaq's declines of -1%.Image Source: Zacks Investment Research AT&T & Verizon’s 5G Growth Sparking investor interest in AT&T and Verizon stock is their continued expansion o ...

INDIANAPOLIS, May 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of imlunestrant, an investigational oral selective estrogen receptor degrader (SERD), olomorasib, an investigational KRAS G12C inhibitor, LY4170156, an investigational antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα) and Verzenio® (abemaciclib; a CDK4/6 inhibitor) will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 - ...

Carnival Co. & TodayCCLCarnival Co. &$22.42 +0.38 (+1.72%) 52-Week Range$13.78▼$28.72P/E Ratio16.13Price Target$26.53Add to WatchlistWhile technological innovation often dominates market attention, a growing number of investors are seeking growth opportunities in less crowded sectors. The global leisure travel industry, currently in a strong recovery, offers such an alternative, with the cruise segment demonstrating significant strength. Reports suggest passenger numbers are recovering and projected to sur ...

VANCOUVER, BC, May 22, 2025 /PRNewswire/ - Today, West Fraser Timber Co. Ltd. ("West Fraser" or the "Company") (TSX: WFG) (NYSE: WFG) released its 2024 Sustainability Report, Building Together: People and Partnerships. The report highlights the Company's sustainability performance across a variety of environmental, social, and governance goals and disclosed targets."Since our founding 70 years ago, West Fraser has recognized our responsibility to the environment and society while delivering solid financial ...

We are currently offering a free two-week trial to Distressed Value Investing . Join our community to receive exclusive research about various companies and other opportunities along with full access to my portfolio of historic research that now includes over 1,000 reports on over 100 companies.Vital Energy, Inc. (NYSE: VTLE ) is now projected to generate around $267 million in 2025 free cash flow at current strip. This is only modestly lower than what I had projected for Vital before oilAaron Chow, aka Ele ...

Core Insights - Astellas Pharma and Pfizer announced five-year follow-up results from the Phase 3 ARCHES study, showing a 30% reduction in the risk of death for men with metastatic hormone-sensitive prostate cancer treated with XTANDI plus androgen deprivation therapy compared to placebo plus ADT [1][5][4] Group 1: Study Results - The five-year follow-up indicated that two-thirds of men are now surviving five years, representing a 13% absolute and 30% relative improvement over standard hormonal therapy alone [2][5] - In patients with high-volume disease, a 36-month improvement in median overall survival was observed, with hazard ratios indicating improved survival across various subgroups [2][5] - The incidence of treatment-emergent adverse events remained consistent with prior analyses, with no new safety signals identified [2][5] Group 2: XTANDI's Impact - XTANDI is recognized for its long-term efficacy and patient impact in advanced prostate cancer, changing the treatment landscape for those living with the disease [3][4] - The five-year follow-up data reinforces XTANDI plus ADT as the standard of care for treating advanced metastatic hormone-sensitive prostate cancer [4][5] Group 3: Future Directions - The results from the ARCHES study will be submitted for publication in a peer-reviewed journal, indicating ongoing research and validation of XTANDI's efficacy [3][4] - Additional data from the eight-year follow-up of the ENZAMET study will also be presented, further supporting the treatment's benefits [4][6] Group 4: Company Background - Astellas Pharma is a global pharmaceutical company focused on addressing diseases with high unmet medical needs, while Pfizer Oncology is committed to delivering transformative therapies in cancer care [26][27] - The collaboration between Astellas and Pfizer for the development and commercialization of XTANDI has been ongoing since 2009, highlighting a long-term partnership in advancing cancer treatment [28]

Core Insights - Wheaton Precious Metals Corp. published its 2024 Sustainability Report and Climate Change Report, emphasizing its commitment to integrating ESG considerations into its operations and decision-making processes [1][2] Sustainability Report Highlights - The 2024 Sustainability Report provides a comprehensive review of Wheaton's performance in environmental, social, and governance (ESG) topics, including updates on its ESG strategy, targets, and commitments [3] - The report indicates that 100% of new streaming agreements in 2024 were screened for ESG issues and risks [7] - Wheaton has contributed over $53 million globally since 2009 through its Community Investment Programs, with more than $8.5 million allocated to charitable causes in 2024 [7] Climate Change Report Highlights - The 2024 Climate Change Report outlines how Wheaton is addressing climate change risks and opportunities, as well as potential climate-related impacts [4] - The company refreshed its climate scenario analysis to support ongoing assessment and management of climate risks [7] - A gap analysis was completed against the International Sustainability Standards Board's S2 standard, leading to updates in the Climate Change Report [7] Standards and Recognition - Wheaton's reports are informed by GRI Standards and SASB Asset Management, and Metals and Mining Standard, as well as the IFRS S2 Climate-Related Disclosures Standard [5] - The company has received top ratings in ESG from various agencies, including Sustainalytics and MSCI, and is recognized among Corporate Knights' most sustainable corporations [7] Governance and Diversity - 50% of Wheaton's board members represent diverse backgrounds, including women and visible minorities [7] - 86% of 2023 Scope 3 financed emissions are covered by emissions reduction targets aligned with a 2°C or less scenario [7]